The best place to discover, build, and manage on-demand life science teams.
Boston, MA
Joined August 2015
- Tweets597
- Following266
- Followers190
- Likes278
Big week for #radiopharma: BMS’s RYZ101, the lead asset from its $4.1B RayzeBio acquisition, hit its Phase 3 primary endpoint, and @GEHealthCare agreed to acquire Sofie Biosciences, a leading U.S. CMO for PET radiopharmaceuticals, for $945M. ow.ly/xv9e50ZXjy3
Why do 9 out of 10 drugs that enter the clinic fail?
@bmsnews Chief Research Officer Robert @rplenge joins @rahulc on @Biotech2050Pod to discuss human #biology, #AI in #drugdiscovery, and why novel targets matter.
His advice: “Hold your why tightly and your how loosely.”
🔬 Can causal human biology change the odds of drug discovery?
BMS Chief Research Officer @rplenge joins @rahulc to explore target diversity, immune reset, AI in R&D, blended innovation & the future of transformative medicines.
🎧 - on.soundcloud.com/5z8XpzDC0q…
#Biotech2050 #Biotech
"Earn the right to grow." On the latest @Biotech2050Pod, @rahulc talks with @KymeraTx CEO @NelloMainolfi about raising capital only after hitting milestones, focusing on #immunology, and why culture matters as much as the #science. Listen to the #podcast now using the link below.
🧬 From a fringe scientific bet to pioneering targeted protein degradation.@KymeraTx CEO @NelloMainolfi joins @rahulc on #Biotech2050 to discuss drug discovery, immunology, disciplined growth & building a culture that can do what’s never been done. 🎧 - on.soundcloud.com/ksNbuIbEJt…
AI #drugdiscovery is having an outsized fundraising year. @enveda just closed a $311M Series E, days after @Basecamp_Res raised $140M. Capital at this scale, this early, changes the question from what to build to who to bring in, and when: ow.ly/yHvE50ZSnTU
Astex, @abbvie, @bmsnews, @JNJNews & @TakedaPharma trained an #AI protein-structure model on proprietary #drugdiscovery data via Apheris's federated platform, without sharing it. It predicted ligand poses correctly 62% more often than the public baseline: ow.ly/b4fS50ZQzh4
Frazier Life Sciences just closed $1.1B in new commitments for its public #biotech fund, pushing total assets to roughly $2.8B — signaling continued appetite for small and mid-cap biotech even as the broader funding environment stays selective: ow.ly/fSoQ50ZOgAa
The federal government is investing up to $125M to rethink how personalized #RNAmedicines are made. ARPA-H’s GIVE program aims to bring manufacturing faster and closer to patients, highlighting the need for specialized expertise to scale: ow.ly/rxEH50ZLtg4 #Biotech #RNA
Biotech is having a real moment. The XBI has climbed from ~$90 to nearly $170 this year. 2026 has already topped 2025's full-year IPO count, and several debuts are trading well above their launch price: ow.ly/Ax0S50ZHrqq #biotech #lifesciences
Big week for personalized medicine: @moderna_tx & @Merck mRNA cancer vaccine, Intismeran, hit its primary endpoint in a Phase 3 melanoma trial with Keytruda—a major milestone for personalized #cancer #vaccines after years of promise. Congrats to both teams!
Moderna and @Merck today announced positive topline results from the Phase 3 INTerpath-001 trial evaluating adjuvant treatment with intismeran autogene, a novel investigational mRNA-based individualized neoantigen therapy jointly developed by Merck and Moderna, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with completely resected Stage IIB-IV melanoma.
Read more:
Congrats to our client @PTCBio on winning the competitive auction for Sangamo’s ST-920, a BLA-stage #genetherapy for Fabry disease. Beating out two other bidders says a lot about conviction. ST-920 could see a potential commercial launch as early as 2027.
PTC Therapeutics was selected as the winning bidder to acquire ST-920 – a BLA-stage one-time administered AAV gene therapy for Fabry disease – from Sangamo Therapeutics in a competitive bankruptcy auction. Learn more: ow.ly/O0ie50Zz6cz
What will it take for #AI to truly transform #drugdiscovery? On the latest @Biotech2050Pod, Clora CEO @rahulc speaks with @nick_myerberg of Braidwell about AI-native #biotech, proprietary data, and the future of discovery. Listen using the link below.
AI won't replace scientists - it will redefine drug discovery
@rahulc talks w/ @nick_myerberg, Partner & Head of AI @braidwell, on AI-native biotech, proprietary data, autonomous labs & why the next decade could transform how medicines are discovered
🎧 - on.soundcloud.com/cUxDlhSnqD…
Clora CEO @rahulc talks with Robert Jacks, CEO of @Sparrow_Pharma, about #biotech #leadership, precision medicine & the future of type 2 #diabetes care. Listen to the full #podcast episode now!
From civil engineer to biotech CEO.
@rahulc speaks with Robert Jacks, CEO of @Sparrow_Pharma, on building sustainable biotech companies, precision medicine, cortisol biology, & the future of treating difficult-to-control diabetes. 🎧 - on.soundcloud.com/hc4cVoW7qs…
#Biotech2050
Congratulations to our client @OrcaBio on the U.S. FDA approval of TREGZI™. We're proud to support organizations advancing innovation in #celltherapy and look forward to seeing the impact of this important milestone.
We are proud to announce the U.S. FDA approval of our new precision-engineered cell therapy for allogeneic transplant in people with hematologic malignancies. This marks a significant milestone for Orca Bio, and most importantly, for the patients we serve.
Learn more: bit.ly/4vGQOU0
#CellTherapy #BloodCancer
Biopharma dealmaking is gaining momentum. PwC reports Q1 M&A deal value surpassed $65B—the strongest start since 2020—signaling renewed confidence across the industry. As companies accelerate #innovation, access to specialized #expertise will be critical.
ow.ly/HTHi50ZepR0
What does it mean to put patients at the center of #biotech? Hear Clora CEO @rahulc talk with @ardelyx CEO Mike Raab & Chief Patient Officer Laura Williams about patient-centric #leadership, resilience, and keeping patients as the North Star through every challenge.
What does patient-centricity look like when embedded in C-suite?
@ardelyx CEO Mike Raab & Chief Patient Officer Laura Williams join @rahulc to share lessons on leadership, perseverance, patient advocacy, & navigating the FDA journey. 🧬❤️ 🎧 - on.soundcloud.com/hIb2q3Oa13… #Biotech2050
Hear Clora CEO @rahulc speak with @AcadiaPharma CEO Catherine Owen Adams about her journey to #biotech #leadership, the future of CNS #innovation, and the forces shaping biotech today. Listen to the full episode.
How do you go from pharmacist to leading a billion-dollar biotech? Catherine Owen Adams, CEO of @AcadiaPharma, joins @rahulc on #Biotech2050 to discuss neuro & rare disease innovation, commercialization, AI, & first-time CEO lessons. 🧠 🎙️- on.soundcloud.com/nXJ0ArsZaZ…
Our new website is live: ow.ly/m7QU50YOvst
15,000+ vetted life sciences consultants. Access in days, not months. Faster than hiring. More flexible than CROs.
#Biotech #LifeSciences
Proud to support our client @C4Therapeutics as they advance targeted #proteindegradation. They just announced an expanded long-term partnership with @Roche, highlighting strong momentum behind their platform. Read more:
ow.ly/TEsP50YKvnR
Biotech doesn’t have a hiring problem—it has a #resourcing strategy problem.
Only 48% of talent needs are met, while specialized roles take 100+ days to fill. Leading companies are rethinking work, bringing in #expertise on demand and prioritizing flexibility to stay on track.
In #biotech and #pharma, speed has been seen as a tradeoff with quality—but that’s changing. Progress now depends on fast access to the right #expertise. Leading teams use agile #talent models to tap global experts on demand, accelerating timelines without compromising rigor.
